Prelude Therapeutics (PRLD) Short-term Investments (2021 - 2026)
Prelude Therapeutics (PRLD) posted Short-term Investments of $59.8 million for Q1 2026, down 12.01% sequentially from $68.0 million in Q4 2025, and up 1.69% YoY from $58.8 million in Q1 2025.
Prelude Therapeutics (PRLD) Short-term Investments (2021 - 2026) Analysis & Trends
Prelude Therapeutics has reported Short-term Investments for 6 years, with the latest figure at $59.8 million in Q1 2026.
- Quarterly Short-term Investments rose 1.69% year-over-year to $59.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.8 million (up 1.69% YoY) and the FY2025 annual result came in at $68.0 million, down 43.9% from the prior year.
- Short-term Investments fell to $59.8 million in Q1 2026 per PRLD's latest filing, from $68.0 million in the prior quarter.
- Over five years, Short-term Investments peaked at $228.5 million in Q2 2023 and troughed at $7.4 million in Q3 2025.
- A 5-year average of $140.7 million and a median of $154.1 million in 2023 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2023 and 2025: Short-term Investments rose 24.76% in 2023, then tumbled 94.79% in 2025.
- Over 5 years, Short-term Investments stood at $171.1 million in 2022, then gained by 21.34% to $207.6 million in 2023, then slumped by 41.66% to $121.1 million in 2024, then plunged by 43.9% to $68.0 million in 2025, then dropped by 12.01% to $59.8 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $59.8 million, $68.0 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125.43 Mn |
| Mar 31, 2026 | 59.80 Mn |
| Dec 31, 2025 | 67.96 Mn |
| Sep 30, 2025 | 7.43 Mn |
| Jun 30, 2025 | 47.46 Mn |
| Mar 31, 2025 | 58.81 Mn |
| Dec 31, 2024 | 121.14 Mn |
| Sep 30, 2024 | 142.49 Mn |
| Jun 30, 2024 | 152.02 Mn |
| Mar 31, 2024 | 177.22 Mn |
| Dec 31, 2023 | 207.64 Mn |
| Sep 30, 2023 | 214.61 Mn |
| Jun 30, 2023 | 228.54 Mn |
| Mar 31, 2023 | 154.05 Mn |
| Dec 31, 2022 | 171.12 Mn |
| Sep 30, 2022 | 172.02 Mn |
| Jun 30, 2022 | 195.60 Mn |
| Mar 31, 2022 | 214.56 Mn |
| Dec 31, 2021 | 259.41 Mn |
| Sep 30, 2021 | 259.44 Mn |